ECSP045221A - Sales de valsartan - Google Patents

Sales de valsartan

Info

Publication number
ECSP045221A
ECSP045221A EC2004005221A ECSP045221A ECSP045221A EC SP045221 A ECSP045221 A EC SP045221A EC 2004005221 A EC2004005221 A EC 2004005221A EC SP045221 A ECSP045221 A EC SP045221A EC SP045221 A ECSP045221 A EC SP045221A
Authority
EC
Ecuador
Prior art keywords
salts
valsartan
crystalline
salt
formula
Prior art date
Application number
EC2004005221A
Other languages
English (en)
Inventor
Erwin Marti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP045221A publication Critical patent/ECSP045221A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

La invención se refiere a nuevas formas de sales de valsartan o cristalinas, también sales de valsartan parcialmente cristalinas y amorfas, la producción y el uso respectivos, y preparaciones farmacéuticas que contienen dicha sal (Fórmula I).
EC2004005221A 2002-02-04 2004-08-04 Sales de valsartan ECSP045221A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35419902P 2002-02-04 2002-02-04

Publications (1)

Publication Number Publication Date
ECSP045221A true ECSP045221A (es) 2004-09-28

Family

ID=27734333

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005221A ECSP045221A (es) 2002-02-04 2004-08-04 Sales de valsartan

Country Status (17)

Country Link
US (3) US6869970B2 (es)
EP (1) EP1474402A1 (es)
JP (2) JP4895475B2 (es)
KR (3) KR20110101257A (es)
CN (2) CN100548993C (es)
AU (1) AU2003214054B2 (es)
BR (1) BR0307442A (es)
CA (2) CA2474424C (es)
CO (1) CO5611107A2 (es)
EC (1) ECSP045221A (es)
MX (1) MXPA04007525A (es)
NO (1) NO328155B1 (es)
NZ (1) NZ534560A (es)
PL (1) PL370481A1 (es)
RU (1) RU2004126862A (es)
WO (1) WO2003066606A1 (es)
ZA (1) ZA200405698B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
AU2003276960A1 (en) * 2002-06-13 2003-12-31 Novartis Ag Calcium salts of indole derived statins
ATE393764T1 (de) * 2003-03-17 2008-05-15 Teva Pharma Polymorphe formen von valsartan
TW200509909A (en) * 2003-05-16 2005-03-16 Novartis Ag Use of organic compounds
CA2544747A1 (en) * 2003-11-14 2005-05-26 Novartis Ag At1-receptor antagonists for treating nephrotic syndrome
WO2005049587A1 (en) * 2003-11-21 2005-06-02 Ranbaxy Laboratories Limited Process for preparation of biphenyl tetrazole
ITMI20032267A1 (it) * 2003-11-21 2005-05-22 Dinamite Dipharma S P A In Forma A Bbreviata Diph Procdimento per la preparzione di valsartan e suoi intermedi
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
EP1586310B1 (de) * 2004-04-15 2006-12-27 Helm AG Verfahren zur Herstellung von freifliessenden, pulverförmigen Valsartan-Adsorbaten
AR050043A1 (es) * 2004-08-03 2006-09-20 Novartis Ag Metodos para mejorar la biodisponibilidad y composicion farmaceutica para trastornos cardiovasculares
WO2006021443A2 (en) * 2004-08-26 2006-03-02 Novartis Ag Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator
US8022086B2 (en) 2004-10-29 2011-09-20 Kowa Co., Ltd. Therapeutic agent for glomerular disease
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
EP2043607A2 (en) * 2006-06-23 2009-04-08 Usv Limited Process for the preparation of micronized valsartan
PE20120542A1 (es) 2006-06-27 2012-05-14 Novartis Ag Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas
WO2008018843A1 (en) * 2006-08-08 2008-02-14 Ulkar Kimya Sanayi Ve Ticaret As Process for producing useful salts form of biphenyl-tetrazole compounds
PE20080907A1 (es) * 2006-08-31 2008-08-22 Novartis Ag Sistema de suministro de farmaco oral gastro-retentivo de liberacion extendida para valsartan
US8080549B2 (en) * 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US8071596B2 (en) 2007-01-12 2011-12-06 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
CN101396366B (zh) * 2007-09-25 2010-10-13 浙江华海药业股份有限公司 含缬沙坦的固体口服制剂及其制备方法
ES2336755B1 (es) * 2008-10-07 2011-01-21 Activery Biotech, S.L. Procedimiento para la preparacion de combinaciones de valsartan y simvastatina.
JP2011063518A (ja) * 2009-09-15 2011-03-31 Tohoku Univ Ａｒｂ及び／又はグリタゾン系血糖降下物質を含有するｏａｔｐ−ｒ遺伝子発現増強組成物
WO2012016969A1 (en) 2010-08-03 2012-02-09 Novartis Ag Highly crystalline valsartan
CN103012301B (zh) * 2013-01-05 2015-06-17 江苏施美康药业股份有限公司 缬沙坦甲酯碱金属盐及其制备方法
DE102014004512A1 (de) * 2014-03-28 2015-10-01 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Bereich Universitätsmedizin Anorganisch-organische Hybridverbindung
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
EP3498698A1 (en) 2017-12-15 2019-06-19 Mankind Pharma Ltd Solid forms of valsartan disodium and process of preparation thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL97219A (en) * 1990-02-19 1995-12-08 Ciba Geigy Ag Biphenyl substituted aliphatic amino compounds process for their preparation and pharmaceutical compositions containing them
BR9604818A (pt) * 1995-04-07 1998-06-09 Novartis Ag Composições de combinação contendo benazepril ou benazeprilat e valsartan
ES2099031B1 (es) 1995-05-31 1997-12-01 Esteve Labor Dr Nuevos polimorfos de diclorhidrato de lesopitron y sus formas hidratadas, procedimientos de preparacion y composiciones que los contienen.
US5877193A (en) * 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
EE9900377A (et) * 1997-02-28 2000-04-17 Burstein Laboratories, Inc. Labor laserkettas
US6641886B1 (en) * 1999-03-23 2003-11-04 Flexplay Technologies, Inc. Directory read inhibitor for optical storage media
JP2001155346A (ja) * 1999-11-26 2001-06-08 Toshiba Corp 情報記録媒体、情報記録装置、情報記録方法、情報再生装置、情報再生方法
ES2277301T3 (es) 2000-04-24 2007-07-01 Teva Pharmaceutical Industries Ltd. Solvato de hemitartrato de zolpidem.
US20020132839A1 (en) * 2000-06-22 2002-09-19 Ganter Sabina Maria Tablet formulations comprising valsartan
DE60135560D1 (de) 2000-07-19 2008-10-09 Novartis Ag Valsartan salze
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan

Also Published As

Publication number Publication date
US8058301B2 (en) 2011-11-15
CN1628106A (zh) 2005-06-15
CN100548993C (zh) 2009-10-14
PL370481A1 (en) 2005-05-30
US8329919B2 (en) 2012-12-11
AU2003214054A1 (en) 2003-09-02
US20050101652A1 (en) 2005-05-12
MXPA04007525A (es) 2004-11-10
RU2004126862A (ru) 2005-06-27
JP2009235086A (ja) 2009-10-15
NO20043660L (no) 2004-10-12
AU2003214054B2 (en) 2007-08-16
NZ534560A (en) 2007-05-31
JP4895475B2 (ja) 2012-03-14
EP1474402A1 (en) 2004-11-10
CA2776902A1 (en) 2003-08-14
US6869970B2 (en) 2005-03-22
CA2474424C (en) 2013-03-26
HK1139681A1 (en) 2010-09-24
JP2005517696A (ja) 2005-06-16
CA2474424A1 (en) 2003-08-14
US20030171414A1 (en) 2003-09-11
ZA200405698B (en) 2006-05-31
KR20120054667A (ko) 2012-05-30
CO5611107A2 (es) 2006-02-28
KR20110101257A (ko) 2011-09-15
CN101633646B (zh) 2012-08-29
KR20040081178A (ko) 2004-09-20
US20120022268A1 (en) 2012-01-26
BR0307442A (pt) 2005-01-04
JP5303370B2 (ja) 2013-10-02
WO2003066606A1 (en) 2003-08-14
NO328155B1 (no) 2009-12-21
CN101633646A (zh) 2010-01-27

Similar Documents

Publication Publication Date Title
ECSP045221A (es) Sales de valsartan
ECSP034436A (es) Sales de valsartan
CY1108101T1 (el) Ενωσεις πυριμιδινης και η χρηση τους στην παρασκευη ενος τριαζολο-πυριμιδιν καρβα νουκλεοζιτη
CR7583A (es) Nueva sal formiato de o-desmetil venlafaxina
AR058433A1 (es) Derivado de 1,1-dioxido de 1,4-benzotiazepina ,procedimiento para su preparacion ,medicamentos que comprenden este compuesto y su uso
BRPI0408347A (pt) derivados de pirimidina
CY1106801T1 (el) Νεες ετεροκυκλικες ενωσεις, η παρασκευη τους και η χρηση τους ως φαρμακα, ιδιαιτερα ως αντιβακτηριακα
UY28040A1 (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos.
HRP20120323T1 (en) Diarylhydantoin compounds
AR061024A1 (es) Maleato de 5-amino-3- (2'3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d] pirimidin-2-ona.
ECSP034460A (es) Nuevos compuestos heterociclicos, su preparacion y su utilizacion como medicamentos, en especial como antibacterianos
ES2571220T3 (es) Clorhidrato de 8-cloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazepina
CY1105994T1 (el) Aναδιαταγμενες πεντανολες, μεθοδος για την παραγωγη αυτων και η χρηση αυτων ως αντιφλεγμονωδων
NO20052884L (no) Substituerte indolpyridinforbindelser som anti-infeksjonsmidler.
BRPI0514372A (pt) inibidores de tiazol de frutose 1, 6-bisfosfatase
AR063188A1 (es) Compuestos intermediarios para la preparacion de trans -5-cloro-2-netil-2,3,3a,12b- tetrahidro-1h-dibenz (2,3:6,7)- oxepina (4,5c) pirrol
CR7684A (es) Derivados de heterobiarilo como inhibidores de metaloproteinas de la matriz
DOP2001000297A (es) Nuevas imidazotriazinonas sustituidas
BR0311984A (pt) Difenilazetidinonas substituìdas cationicamente, processo para a sua preparação, medicamentos contendo estes compostos e sua aplicação
BR0114379A (pt) Derivados de c-ciclohexilmetilamina substituìdos
ATE441630T1 (de) Substituierte cyclopenten-verbindungen
BRPI0617655A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
BR0312996A (pt) Sal de (s)-pantoprazol e seus hidratos
CL2003002588A1 (es) Uso de una composicion farmaceutica que comprende acido n,n-dimetoximetildifenil barbiturico, acido n-metoximetildifenil barbiturico o acido difenil barbiturico o una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el t
BRPI0415034A (pt) derivados de aminopiridina como inibidores de não-sintase induzìveis